About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 494 record(s)
Req # A-2020-001440
Adverse Reaction Reports (AERs) for ANTI-THYMOCYTE GLOBULIN (RABBIT). Report numbers: 910263, 910897, E2B_02998311, E2B_03152450, E2B_03052153, E2B_03058286, E2B_03058300, E2B_03058305, E2B_03058308, E2B_03058312, E2B_03058315, E2B_03058318,…Organization: Health Canada
April 2021
Req # A-2020-001441
Adverse Reaction Reports (AERs) for ANTI-THYMOCYTE GLOBULIN (RABBIT). Report numbers: E2B_03058764, E2B_03058773, E2B_03058779, E2B_03062549, E2B_03062567, E2B_03062578, E2B_03062587, E2B_03062592, E2B_03064020, E2B_03064028, E2B_03064032,…Organization: Health Canada
April 2021
Req # A-2020-001470
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-123456-504, 2020 Association of Professional Executives of the Public Service - Awards of Excellence.Organization: Health Canada
April 2021
Req # A-2020-001477
Adverse Reaction Reports (AERs) for LEFLUNOMIDE. Report numbers: E2B_03081785 E2B_03081978 E2B_03081992 E2B_03072117 E2B_03072575 E2B_03072817 E2B_03072637 E2B_03073584 E2B_03073614 E2B_03071730 E2B_03082293 E2B_03043994 E2B_03044121.Organization: Health Canada
April 2021
Req # A-2020-001541
Adverse Reaction Reports (AERs) for Isentress. Report numbers: E2B_00387327, E2B_00499641, E2B_00499643, E2B_00501466, 000634758, 000634763, E2B_00328905, E2B_00546820, E2B_00548262, E2B_00646371, E2B_01199359, E2B_01199371, E2B_01199373.Organization: Health Canada
April 2021
Req # A-2020-001570
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-075486-393.Organization: Health Canada
April 2021
Req # A-2020-001589
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_02966022.Organization: Health Canada
April 2021
Req # A-2020-001590
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03343424.Organization: Health Canada
April 2021
Req # A-2020-001591
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03230625.Organization: Health Canada
April 2021
Req # A-2020-001592
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03346550.Organization: Health Canada
April 2021